LENZ
LENZ TherapeuticsยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
LENZ Profile
Lenz Therapeutics, Inc.
A clinical late-stage biopharmaceutical company focused on developing innovative ophthalmic drugs for the treatment of presbyopia
Biological Technology
06/01/2017
06/25/2021
NASDAQ Stock Exchange
42
12-31
Common stock
201 Lomas Santa Fe Dr., Suite 300, Solana Beach, California 92075
--
LENZ Therapeutics, Inc., was incorporated in Ontario, Canada on June 1, 2017 and re-registered in Delaware in October 2019. They are a clinical-stage next-generation gene-editing company developing novel therapies with highly effective targeted gene integration that have the potential to cure a wide range of serious and life-threatening diseases. They are pioneering a precise method of gene editing to achieve one of the most elusive goals in medicine: to precisely "find and replace" any gene in the genome. Their next-generation gene-editing platform allows them to precisely correct mutations, replace entire disease-causing genes with normal genes, or insert new genes into predetermined safe locations.
